Vaxcyte (PCVX) Cash & Equivalents (2019 - 2026)
Vaxcyte (PCVX) posted quarterly Cash & Equivalents of $260.8 million for Q1 2026, down 24.8% year-over-year from $346.8 million in Q1 2025, and up 49.95% quarter-over-quarter from $174.0 million in Q4 2025.
Vaxcyte (PCVX) Cash & Equivalents (2019 - 2026) Analysis & Trends
Vaxcyte (PCVX) has reported Cash & Equivalents for 8 consecutive years, with $260.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents fell 24.8% year-over-year to $260.8 million; the TTM figure through Mar 2026 stood at $260.8 million (down 24.8% YoY), while the FY2025 annual figure was $174.0 million, down 55.15% from the prior year.
- Cash & Equivalents climbed to $260.8 million in Q1 2026 per PCVX's latest filing, from $174.0 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $1.1 billion in Q3 2024 and bottomed at $174.0 million in Q4 2025.
- Historically, Cash & Equivalents has averaged $432.0 million across 5 years, with a median of $380.5 million in 2023.
- Annual changes were most pronounced in 2022 — Cash & Equivalents surged 1109.91% — and 2025, when it sank 73.24%.
- Vaxcyte's Cash & Equivalents stood at $834.7 million in 2022, then plunged by 52.38% to $397.5 million in 2023, then dropped by 2.41% to $387.9 million in 2024, then slumped by 55.15% to $174.0 million in 2025, then jumped by 49.95% to $260.8 million in 2026.
- Business Quant data shows PCVX's Cash & Equivalents at $260.8 million in Q1 2026, $174.0 million in Q4 2025, and $281.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Vaxcyte | 8.41 Bn | 8.41 Bn | - | 183.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 183.19 Mn |
| Mar 31, 2026 | 260.84 Mn |
| Dec 31, 2025 | 173.96 Mn |
| Sep 30, 2025 | 281.08 Mn |
| Jun 30, 2025 | 306.74 Mn |
| Mar 31, 2025 | 346.85 Mn |
| Dec 31, 2024 | 387.88 Mn |
| Sep 30, 2024 | 1.05 Bn |
| Jun 30, 2024 | 518.67 Mn |
| Mar 31, 2024 | 611.51 Mn |
| Dec 31, 2023 | 397.45 Mn |
| Sep 30, 2023 | 545.13 Mn |
| Jun 30, 2023 | 531.03 Mn |
| Mar 31, 2023 | 380.45 Mn |
| Dec 31, 2022 | 834.66 Mn |
| Sep 30, 2022 | 278.40 Mn |
| Jun 30, 2022 | 238.17 Mn |
| Mar 31, 2022 | 201.74 Mn |
| Dec 31, 2021 | 68.99 Mn |
| Sep 30, 2021 | 112.04 Mn |